New drug aims to tame antibodies in rare clotting disorder
NCT ID NCT06315530
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether the drug telitacicept can reduce levels of harmful antibodies in 20 people with antiphospholipid syndrome, a condition that raises the risk of blood clots. Participants received either telitacicept plus standard care or standard care alone for 48 weeks. The main goal was to see if antibody levels dropped, not yet to prove it prevents clots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
telitacicept
What this could lead to
If it works, this could point toward a new way to reduce dangerous antibodies and prevent blood clots in people with antiphospholipid syndrome.
What could go wrong
This is a very small, early-phase trial with only 20 people. It only measures antibody levels, not whether it actually prevents clots. Side effects are not yet well understood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME (APS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China